| 2.455 -0.035 (-1.41%) | 09-16 12:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.29  |
1-year : | 3.57 |
| Resists | First : | 2.82 |
Second : | 3.05 |
| Pivot price | 2.65 |
|||
| Supports | First : | 2.44 |
Second : | 2.03 |
| MAs | MA(5) : | 2.51 |
MA(20) : | 2.7 |
| MA(100) : | 2.82  |
MA(250) : | 2.97 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7 |
D(3) : | 6.8 |
| RSI | RSI(14): 31.6 |
|||
| 52-week | High : | 4.53 | Low : | 2.18 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ FBIO ] has closed above bottom band by 5.1%. Bollinger Bands are 23.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.54 - 2.55 | 2.55 - 2.56 |
| Low: | 2.42 - 2.44 | 2.44 - 2.46 |
| Close: | 2.46 - 2.49 | 2.49 - 2.51 |
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
Tue, 08 Sep 2026
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Tue, 01 Sep 2026
Passive stake disclosed in Fortress Biotech (NASDAQ: FBIO) by Millennium group - Stock Titan
Sun, 23 Aug 2026
FBIO | Fortress Biotech, Inc. Financials - Revenue Breakdown - Quiver Quantitative
Thu, 30 Jul 2026
Fortress Biotech Just Netted $159 Million - Its Preferred Shares Could Be The Real Winner - Seeking Alpha
Mon, 27 Jul 2026
Fortress Biotech Inc. (FBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Sat, 25 Jul 2026
Fortress Biotech, Inc. Revenue Breakdown – NASDAQ:FBIO - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 22.7 (%) |
| Held by Institutions | 31.4 (%) |
| Shares Short | 5,580 (K) |
| Shares Short P.Month | 5,380 (K) |
| EPS | 2.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.92 |
| Profit Margin | 163.3 % |
| Operating Margin | -53.5 % |
| Return on Assets (ttm) | -7.8 % |
| Return on Equity (ttm) | 115.9 % |
| Qtrly Rev. Growth | 14 % |
| Gross Profit (p.s.) | 1.29 |
| Sales Per Share | 2.05 |
| EBITDA (p.s.) | -0.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 126 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | 0.88 |
| PEG Ratio | 0 |
| Price to Book value | 0.49 |
| Price to Sales | 1.19 |
| Price to Cash Flow | 0.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|